This is not trading/investment advice For good background on the PALISADE trial and Aimmune Therapeutics, check out my prior blog post: https://breakingbiotech.com/2017/10/09/going-nuts-for-oral-immunotherapy-aimt/ -MDGL drop this week on no news is a buying opportunity, if you haven't taken a position -ADMS drop has more merit. I'm waiting to see what they say about this paragraph IV notice https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm047676.htm#p3 -Aimmune Therapeutics shows very solid Phase 3 data for their desensitization therapy and treatment AR101 https://www.aimmune.com/

-Today I talk about Madrigal Pharmaceuticals and their recent Phase 2 data announcement of MGL-3196 effects in HeFH patients -The stock has good long-term potential, their drug shows a profound effect on blood lipids and cholesterol -Look out for final NASH biopsy data in May-2018 https://breakingbiotech.com/2018/03/06/madrigal-pharma-shows-positive-phase-2-data-in-hefh/ https://breakingbiotech.com/2018/01/16/madrigals-nash-candidate-a-winner/

-ADMS stock price takes a hit after FDA approval of Osmolex ER and Delaware judicial decision. -I still believe the company has major upside. http://files.shareholder.com/downloads/AMDA-2MCUO2/6060881861x0x970827/E15BD699-5A1F-4AC9-AEA7-5820EAED669C/ADAMASCorpPresentationFebruary18_v1.0.pdf